Washington — NIOSH is looking for participants for a soon-to-launch registry intended to aid research on understanding and preventing firefighters’ risk of cancer.

Oslo, Norway — Offshore petroleum workers engaged in rotating shift work may face increased risk of prostate cancer, according to the results of a recent study.

Montreal — Women employed in hairdressing, construction and accounting may face a higher risk of developing ovarian cancer, a recent study out of Canada suggests.

Madrid — Solar ultraviolet radiation and diesel engine exhaust emissions top the list of most frequent exposures that put European workers at risk for cancer, results of a recent survey show.

Gaithersburg, MD — Wear and tear in firefighters’ protective clothing may lead to an increased release of chemicals linked to cancer, according to a new study from the National Institute of Standards and Technology.

Houston – Vietnam War veterans who were exposed to the herbicide Agent Orange may have an increased risk of developing skin cancer, according to a new study from researchers at the University of Texas MD Anderson Cancer Center.

Rosemont, IL — Members of the military may face an increased risk of developing skin cancer, according to a recent study from the American Academy of Dermatology.

Washington — In response to multiple studies showing that firefighters are at an increased risk for many types of cancers, the National Volunteer Fire Council and four other organizations have developed a poster intended to help firefighters understand their risks and take action to protect themselves.

Calgary, Alberta — Young workers in construction and other outdoor industries are “key groups that warrant further investigation” into their increased risk of carcinogen exposures on the job, according to a team of Canadian researchers.

Iowa City, IA – A new campaign is reminding farmers about the dangers of skin cancer and heat stress, and how to stay protected.

New York – The risk of developing lung cancer increases when workers smoke, are exposed to asbestos and have asbestosis, according to a new study from the American Thoracic Society.

The American Academy of Dermatology cautions outdoor workers to be aware of an invisible hazard: the sun’s ultraviolet rays. Exposure to these rays for hours is a major risk factor for a number of skin cancers, including melanoma – the most serious form.

Washington — NIOSH has added all types of uterine cancer to the list of health-related conditions covered by the agency’s World Trade Center Health Program.

The post 2024 Cancer Progress Report was curated by information for practice.

Systematic reviews and meta-analyses reveal the importance of an accepting attitude towards cancer for mental health and functional coping. The aim of this study was to examine the psychometric properties of t… Read the full article ›

The post Peace, equanimity and acceptance in the cancer experience: validation of the German version (PEACE-G) and associations with mental health, health-related quality of life and psychological constructs was curated by information for practice.

Cancer affects not only the person with the disease but those around them. Being a family member is described as strenuous and, often, associated with stress, anxiety and feelings of loneliness. There is a hei… Read the full article ›

The post Together but still alone – A qualitative study exploring how family members of persons with incurable oesophageal or gastric cancer manage everyday life was curated by information for practice.

More people are getting cancer in their 20s, 30s, and 40s, and surviving, thanks to rapid advancement in care. Many will have decades of life ahead of them, which means they face greater and more complex challenges in survivorship. Lourdes Monje is navigating these waters at age 29.

Christian author and pro-life activist Ryan Bomberger has announced that his cancer is in remission three months after surgery.

A personal tribute has been paid to one of England’s most beloved Christian comedians Steve Legg after he died on Monday following a brave battle against cancer lasting 17 months. 

US scientists have reaffirmed the benefits of eating walnuts in a new study. Specialists from the University of California at Davis conducted a series of experiments on a group of male mice diagnosed with prostate cancer. The mice were divided into three diet groups. The first group did not consume walnuts, the second group received walnuts, and the third one was fed with walnut oil. The experiment showed that the development of the tumor and malignant cells significantly slowed among the rodents in the second and the third groups. According to Natural News, the scientists explained the success of the experiment with the content of powerful phytonutrients in raw walnuts. This natural product contains that inhibit cancer cells and prevent them from developing.Just two handfuls of walnuts every day reduces the risk of cancer by almost 50 percent, the scientists said.Furthermore, walnut oil reduces the amount of harmful cholesterol in blood and increases insulin sensitivity, which helps fight heart disease and reduces the risk of diabetes. For example, one study found that overweight adults with type 2 diabetes who consumed just one-quarter cup of walnuts daily reduced their fasting insulin levels in just a few months' time compared to those on non-walnut diets. It is believed that walnuts can shrink levels of the hormone IGF-1, known to play a key role in development of both prostate and breast cancer, Natural News says.Thanks to their omega-3 fat content, walnuts are often the subjects of cancer-preventive studies. However, one should be cautious with eating them as walnuts are a high calorie product. For example, just 2.6 ounces of walnuts is about 482 calories, which may - in some people - contribute to an excess of stored fat. Health benefits of walnuts have been known since time immemorial. Hippocrates and Avicenna mentioned them in the treatment of various diseases. In addition, the ancients thought that they stimulate mental activity. Anna Protsenko, a nutritionist, told MedPulse.ru. "Walnuts contain a great deal of minerals," the expert explains. "They include iron, copper, cobalt, potassium, sodium, phosphorus, magnesium, calcium, and iodine. Many of them are antioxidants. In addition, walnuts contain unsaturated fatty acids, more than 20 amino acids, and vitamins A, E, B, P and C. By the way, they contain nearly 50 times more vitamin C than citrus, and 8 times more than black currants. In addition, walnuts are rich in protein.

LDPR leader Vladimir Zhirinovsky managed to get revaccinated. For the first time, the politician chose Sputnik V; for the repeated procedure, he opted for CoviVac. As Zhirinovsky explained, "the level of antibodies is gradually decreasing, I wanted to strengthen the defense of my body." Mass vaccination against coronavirus, which is now taking place in all countries, including Russia, still raises a huge number of questions. This is not surprising, given the fact that the coronavirus infection with which we are dealing has not been thoroughly studied yet, and the vaccines for it have not gone through all the required stages of clinical trials. Pravda.R asked most burning questions related to the topic of vaccination to Professor of Virology, Chief Researcher at the Gamaleya Research Center for Epidemiology and Microbiology Anatoly Alshtein.

The United States has stopped research into new cancer treatments in Russia, Andrey Kaprin, oncologist at the Russian Ministry of Health, General Director of the National Medical Research Center of Radiology said. According to the expert, the United States independently refused to continue research into new cancer therapy. In particular, the US stopped cooperation on protocols. The corresponding decision of the United States has not affected cancer patients in Russia. On the contrary, domestic fundamental science was given a powerful impetus for development, he noted. "The most important thing that we have come to realise is that we need to create our own,” said the oncologist.

Smoking vapes and electronic cigarettes may lead to the development of a new lung disease that was dubbed as EVALI (E-cigarette and Vaping use-Associated Lung Injury). Research works to study EVALI slowed down with the onset of the coronavirus pandemic due to the similarity of symptoms, whereas the detection rate stopped growing, the Russian Health Ministry said. Symptoms of EVALI similar to those of COVID-19 Symptoms of the new disease are in many ways similar to symptoms of COVID-19. They include:

UCLA investigators have shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

These miniature immune system models -- known as human immune organoids -- mimic the real-life environment where immune cells learn to recognize and attack harmful invaders and respond to vaccines. Not only are these organoids powerful new tools for studying and observing immune function in cancer, their use is likely to accelerate vaccine development, better predict disease treatment response for patients, and even speed up clinical trials.

Childhood trauma can increase a breast cancer survivor's chance of experiencing more severe and longer-lasting treatment-related anxiety, depression and fatigue, as well as reduced cognitive function, years after cancer treatment has ended, according to a preliminary study led by Jamie Myers, Ph.D., FAAN, research associate professor at the University of Kansas School of Nursing.

Only half of people with early-onset cancers reported discussing fertility preservation options prior to their oncology treatments, according to results of a cross-sectional study published Nov. 12 in JAMA Network Open.

At six years old, Luke Bucciarelli (pronounced BOO-cha-relli) already knows he wants to be a surgeon when he grows up. But not just any surgeon - a thoracic surgeon; someone who operates on organs in the chest, including the lungs, esophagus, trachea and heart.

These miniature immune system models -- known as human immune organoids -- mimic the real-life environment where immune cells learn to recognize and attack harmful invaders and respond to vaccines. Not only are these organoids powerful new tools for studying and observing immune function in cancer, their use is likely to accelerate vaccine development, better predict disease treatment response for patients, and even speed up clinical trials.

Childhood trauma can increase a breast cancer survivor's chance of experiencing more severe and longer-lasting treatment-related anxiety, depression and fatigue, as well as reduced cognitive function, years after cancer treatment has ended, according to a preliminary study led by Jamie Myers, Ph.D., FAAN, research associate professor at the University of Kansas School of Nursing.

Only half of people with early-onset cancers reported discussing fertility preservation options prior to their oncology treatments, according to results of a cross-sectional study published Nov. 12 in JAMA Network Open.

Discover if Cancer and Pisces compatibility creates a strong, harmonious bond. Dive into emotional insights and learn what makes these water signs connect so deeply.

Discover the compatibility between Cancer and Aquarius in love, friendship, and relationships. Learn how their emotional and intellectual traits align or clash.

Explore reversed Pisces and Cancer compatibility! Learn how these water signs bond emotionally, support each other deeply, and thrive together in relationships.

Explore Cancer and Taurus compatibility, where stability meets sensitivity. Learn how these signs create lasting love through trust, loyalty, and mutual understanding.

This report presents a comprehensive investigation into the synthesis and characterization of Schiff base com­pounds derived from benzene­sul­fon­amide. The synthesis process, involved the reaction between N-cyclo­amino-2-sulf­anil­amide and various substituted o-salicyl­aldehydes, resulted in a set of com­pounds that were subjected to rigorous characterization using advanced spectral techniques, including 1H NMR, 13C NMR and FT–IR spectroscopy, and single-crystal X-ray diffraction. Furthermore, an in-depth assessment of the synthesized com­pounds was conducted through Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) analysis, in conjunction with docking studies, to elucidate their pharmacokinetic profiles and potential. Impressively, the ADMET analysis showcased encouraging drug-likeness properties of the newly synthesized Schiff bases. These computational findings were substanti­ated by mol­ecular properties derived from density functional theory (DFT) calculations using the B3LYP/6-31G* method within the Jaguar Module of Schrödinger 2023-2 from Maestro (Schrodinger LLC, New York, USA). The ex­plor­ation of frontier mol­ecular orbitals (HOMO and LUMO) enabled the computation of global reactivity descriptors (GRDs), encompassing charge separation (Egap) and global softness (S). Notably, within this analysis, one Schiff base, namely, 4-bromo-2-{N-[2-(pyr­rol­idine-1-sul­fonyl)phenyl]car­box­imid­oyl}phenol, 20, em­erged with the smallest charge separation (ΔEgap = 3.5780 eV), signifying heightened potential for biological properties. Conversely, 4-bromo-2-{N-[2-(piper­idine-1-sul­fonyl)phenyl]car­box­imid­oyl}phenol, 17, exhibited the largest charge separation (ΔEgap = 4.9242 eV), implying a relatively lower propensity for biological activity. Moreover, the synthesized Schiff bases displayed re­marke­able inhibition of tankyrase poly(ADP-ribose) polymerase enzymes, integral in colon cancer, surpassing the efficacy of a standard drug used for the same purpose. Additionally, their bioavailability scores aligned closely with established medications such as trifluridine and 5-fluoro­uracil. The ex­plor­ation of mol­ecular electrostatic potential through colour mapping delved into the electronic behaviour and reactivity tendencies intrinsic to this diverse range of mol­ecules.

The complex [Pt(C9H6NO)Cl(C2H4)], (I), was synthesized and structurally characterized by ESI mass spectrometry, IR, NMR spectroscopy, DFT calculations and X-ray diffraction. The results showed that the deprotonated 8-hy­droxy­quinoline (C9H6NO) coordinates with the PtII atom via the N and O atoms while the ethyl­ene coordinates in the η2 manner and in the trans position compared to the coordinating N atom. The crystal packing is characterized by C—H⋯O, C—H⋯π, Cl⋯π and Pt⋯π inter­actions. Complex (I) showed high selective activity against Lu-1 and Hep-G2 cell lines with IC50 values of 0.8 and 0.4 µM, respectively, 54 and 33-fold more active than cisplatin. In particular, complex (I) is about 10 times less toxic to normal cells (HEK-293) than cancer cells Lu-1 and Hep-G2. Furthermore, the reaction of complex (I) with guanine at the N7 position was proposed and investigated using the DFT method. The results indicated that replacement of the ethyl­ene ligand with guanine is thermodynamically more favorable than the Cl ligand and that the reaction occurs via two consecutive steps, namely the replacement of ethyl­ene with H2O and the water with the guanine mol­ecule.

Source: Dr. David Nierengarten 11/07/2024

TScan Therapeutics Inc. (TCRX:NASDAQ) Phase 1 ALLOHA study, evaluating its lead therapeutic candidates TSC-100 and TSC-101 in hematologic malignancies, showed patients continuing to have a positive response after one year, reported Wedbush analyst Dr. David Nierengarten in a Nov. 5 research note. TSC-100 and TSC-101 are T-cell receptor-engineered T-cell therapies (TCR-Ts).

"We see a catalyst-rich next few months ahead with data building in prominence on stock impact," Nierengarten wrote.

87% Return Potential

Wedbush has a US$10 per share target price on the Massachusetts-based biotech, trading at the time of the report at about US$5.36 per share, noted the analyst. The difference between these figures implies an 87% return potential for investors.

TScan Therapeutics remains rated Outperform.

Durability of Response Data

Nierengarten presented the clinical trial's latest results. As of the July 8, 2024 data cutoff date, in Phase 1 of ALLOHA, 16 patients with hematologic tumors had been administered TSC-100 or TSC-101, and 11 patients had been given a placebo. Median follow-ups had occurred at 5.8 months and 5.3 months, respectively.

At the time, none of the patients in the treatment arm had had a relapse. In the control arm, however, three, or 27% of, the 11 patients had, and the median time to relapse was 159 days. The analyst explained that this is typical for patients receiving a hematopoietic stem cell transplant after reduced-intensity conditioning.

One year out from treatment, five patients were evaluable, and all remained relapse free and minimal residual disease negative at the time. These data underscore the durability of response to this TCR-T treatment, Nierengarten commented. Its safety profile was shown to be favorable still, with no patients experiencing dose-limiting toxicities or adverse events associated with allogeneic hematopoietic cell transplantation.

"Enrollment continues in dose expansion cohorts, and results could support a registrational trial as early as 2025, pending regulatory feedback," Nierengarten wrote.

On the Horizon

TScan Therapeutics has several catalysts related to its clinical programs on the horizon, which Nierengarten listed.

On Nov. 8 and 9, the company will present preclinical data in the poster sessions at the annual Society for Immunotherapy of Cancer meeting. One poster will show in vitro combinatorial data for T-Plex, TScan's cellular therapy for treating solid tumors. It is comprised of two to three different TCR-Ts that target different tumor antigens on different human leukocyte antigen (HLA) types.

A second poster will detail the expansion of ImmunoBank, the biotech's diverse bank of therapeutic T-cell receptors (TCRs) that recognize diverse targets and are associated with multiple HLA types. The third will depict development of a target agnostic platform to evaluate how TCR-Ts affect primary human tissues.

On Dec. 9, TScan Therapeutics will present updated one-year data from ALLOHA, at the American Society for Hematology Annual Meeting in December.

By year-end, the biotech will announce initial data from administering singleplex therapy, cell therapy engineered using a single TCR, to patients with solid tumors. This treatment is being given to establish safety before administering multiplex therapy, cell therapy engineered from multiple TCRs.

In 2025, TScan Therapeutics will provide long-term duration of response data for multiplex therapy in solid tumors and will potentially commence a registrational trial for TSC-100 and TSC-101.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, TScan Therapeutics Inc., November 5, 2024

Analyst Certification We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

Company Specific Disclosures This information is subject to change at any time. 1. WS makes a market in the securities of TScan Therapeutics, Inc.. 6. WS is acting as a financial advisor for TScan Therapeutics, Inc..

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: TCRX:NASDAQ, )

Smokers who are exposed to radon appear to be at even greater risk for lung cancer, because the effects of smoking and radon are more powerful when the two factors are combined, says a new report by a committee of the National Research Council.

Scientific evidence is insufficient to prove or disprove the theory that exposure to polio vaccine contaminated with a monkey virus between 1955 and 1963 has triggered cancer in humans, says a new report from the Institute of Medicine of the National Academies.

Ovarian cancer should not be categorized as a single disease, but rather as a constellation of different cancers involving the ovary, yet questions remain on how and where various ovarian cancers arise, says a new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine.

Current cancer control efforts in the United States typically are fragmented and uncoordinated, but taking a systems approach to establish a U.S. National Cancer Control Plan would address the challenge more holistically, says a new report from the National Academies of Sciences, Engineering, and Medicine.

COVID-19 cases are surging again in parts of the U.S., but that doesn’t mean other medical issues can be put on hold. Cancer care is particularly complex in the age of COVID-19, said panelists during a July 13 and 14 National Academies webinar, Opportunities and Challenges for Using Digital Health Applications in Oncology. It involves a spectrum of services — including screening, diagnostics, surgery, radiation, palliative care, and survivorship care.

Survivors of childhood cancer have an increased risk of experiencing disabling conditions, both from the cancer itself and from the effects of treatment, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Although cancer survivors are living longer, cancer and its treatment can result in long-lasting or late-onset impairments that may affect their ability to work, says a new report from the National Academies of Sciences, Engineering, and Medicine.

As NASA prepares to send astronauts to the moon and Mars, it is revisiting the latest research on cancer risk from space radiation. A new report recommends NASA proceed with setting a new radiation exposure limit, and improve how it communicates cancer risk to astronauts.

Equitable cancer care starts with prevention and reaching people well before they become patients. Panelists at a recent workshop discussed how cancer centers can weave health equity into everything they do, from creating jobs to helping survivors manage treatment side effects.

For the first time, researchers from the Wellcome Trust Sanger Institute and their collaborators have been able to identify in human cancers two characteristic patterns of DNA damage caused by ionising radiation. These fingerprint patterns may now enable doctors to identify which tumours have been caused by radiation, and investigate if they should be treated differently.

read more